Sun Pharma gets nod from South African regulator for generic semaglutide injection
Sun Pharmaceutical Industries has received approval from South African regulators to manufacture and market a generic version of the semaglutide injection. The drug, used for treating type 2 diabetes, will be available as a pre-filled, multi-dose injectable pen.
Why it matters
This expansion increases access to affordable diabetes medication in South Africa, addressing a growing public health challenge in the region.
Sun Pharmaceutical Industries Ltd. on Wednesday (July 15, 2026) said it has received approval from the South African regulator to manufacture and market a generic version of semaglutide injection in the country for treatment of adults with type 2 diabetes mellitus.
The approval by the South African Health Products Regulatory Authority (SAHPRA) is to manufacture and market the generic version of semaglutide injection in South Africa for the treatment of adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise, Sun Pharmaceutical Industries said in a regulatory filing. The company plans to launch the product in the market in the coming days.
It will be available as a pre-filled, multi-dose injectable pen in two strengths (2 mg/1.5 mL and 4 mg/3 mL) that allow flexible, once-weekly dosing, it added.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in